TG Therapeutics, Inc. develops and commercializes biopharmaceutical therapies for the treatment of B-cell mediated diseases, with a primary focus on multiple sclerosis (MS). Its lead product, BRIUMVI (ublituximab), is indicated for treating relapsing forms of MS in adults. The company operates primarily in the United States and is engaged in advancing a pipeline of therapies targeting various B-cell mediated conditions.
- Website
- tgtherapeutics.com
- Issuer profile
- All listings